Plain-English translation of NCT05938712 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications—semaglutide and dapagliflozin—can safely work together to protect your heart and kidney function after a kidney transplant. Both medications were originally developed to help with blood sugar control, but research shows they also lower blood pressure in the kidneys and may protect kidney function long term. This study will be one of the first to see if using them together is safe and effective for transplant recipients.
While kidney transplants greatly improve survival and quality of life, there are limited treatment options to protect both the heart and the transplanted kidney over time. Each medication has shown promise on its own in smaller studies, but no one has yet studied whether using them together is safe or offers additional benefits in transplant recipients.
You likely qualify if…
You likely don't qualify if…
Over 24 weeks, you would first take one medication alone for 12 weeks, then add the second medication for another 12 weeks. During the study, you would visit the research team multiple times for blood tests, urine tests, blood pressure checks, and heart and kidney imaging to see how the medications affect your body. The medications are given as a daily tablet and a once-weekly injection.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada